Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
$21.60 +0.82 (3.95%)
As of 08/12/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.